title: Effects of octreotide on circulating islet B cell products in endogenous hyperinsulinism.
abstract: The role of somatostatin analogues in the medical management of insulinomas is unclear. We describe an elderly patient with clinical and biochemical features of endogenous hyperinsulinism attributable to a benign islet B cell disorder whose incapacitating neuroglycopaenic symptoms responded dramatically to octreotide 50 micrograms subcutaneously at 2200 h each night. Octreotide suppressed inappropriate plasma concentrations of insulin thereby preventing fasting hypoglycaemia. Fasting concentrations of proinsulin, and 32-33 split proinsulin, as determined by two-site monoclonal antibody-based immunoradiometric assays, were also suppressed by octreotide.
authors.affiliation: Diabetic Clinic, General Hospital, Birmingham, UK.
authors.forename: A J
authors.initials: AJ
authors.lastname: Krentz
authors.forename: J
authors.initials: J
authors.lastname: Pace
authors.forename: W
authors.initials: W
authors.lastname: Somerville
authors.forename: P M
authors.initials: PM
authors.lastname: Clark
authors.forename: M
authors.initials: M
authors.lastname: Nattrass
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D006946:Hyperinsulinism / Q000188:drug therapy*; D007003:Hypoglycemia / Q000517:prevention & control; D007340:Insulinoma / Q000150:complications*; D008297:Male; D015282:Octreotide / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000150:complications*
chemical_list: D015282:Octreotide